Neuropace
NPCE
24 hedge funds and large institutions have $25.9M invested in Neuropace in 2022 Q4 according to their latest regulatory filings, with 1 funds opening new positions, 9 increasing their positions, 6 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 6
3.38% less ownership
Funds ownership: 73.08% → 69.71% (-3.4%)
14% less funds holding
Funds holding: 28 → 24 (-4)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
51% less capital invested
Capital invested by funds: $53.1M → $25.9M (-$27.2M)
75% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$237K |
| 2 |
Morgan Stanley
New York
|
+$144K |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$77.8K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$52.6K |
| 5 |
Bank of America
Charlotte,
North Carolina
|
+$24.9K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$1.46M |
| 2 |
American Century Companies
Kansas City,
Missouri
|
-$718K |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$546K |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$436K |
| 5 |
E
Ergoteles
New York
|
-$116K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
OM
26
Opaleye Management
Boston,
Massachusetts
| – | -$436K | -116,324 | Closed |
|
|
E
27
Ergoteles
New York
| – | -$116K | -31,027 | Closed |
|
28
Royal Bank of Canada
Toronto,
Ontario, Canada
| – | -$380 | -171 | -75% |
|
NPCE Hedge Fund Activity: Q4 2022 in Review
24 of the 6,221 institutional investors tracked by Wall St. Rank reported a position in Neuropace (NPCE) for Q4 2022, worth a combined $25.9M — down 51% from $53.1M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of NPCE and 1 opened new positions — a net loss of 3 holders — while 6 trimmed existing stakes and 9 added.
The largest buyer was Millennium Management, adding an estimated $237K. The largest seller was Bellevue Group, exiting entirely with an estimated $1.46M sold.
- 24 institutional investors held Neuropace (NPCE) as of Q4 2022, down from 28 in Q3 2022.
- Funds reported $25.9M of Neuropace stock for Q4 2022, down 51% quarter-over-quarter.
- 1 fund opened new Neuropace positions in Q4 2022 and 4 closed out, a net change of -3 holders.
- The largest Neuropace buyer in Q4 2022 was Millennium Management, an estimated $237K added.
- The largest Neuropace seller in Q4 2022 was Bellevue Group, an estimated $1.46M sold.
Based on aggregated 13F filings for Q4 2022.